



## Syndax Announces Participation at Two Upcoming Investor Conferences

February 1, 2024

WALTHAM, Mass., Feb. 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in two upcoming investor conferences:

- A fireside chat at the Guggenheim 6th Annual Biotechnology Conference at 10:00 a.m. ET on Thursday, February 8, 2024 in New York, NY.
- A fireside chat at the Citi 2024 Virtual Oncology Leadership Summit at 2:00 p.m. ET on Wednesday, February 21, 2024.

A live webcast of the fireside chats can be accessed from the Investor section of the Company's website at [www.syndax.com](http://www.syndax.com), where a replay of the events will also be available for a limited time.

### About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit [www.syndax.com](http://www.syndax.com) or follow the Company on [Twitter](#) and [LinkedIn](#).

### Syndax Contacts

Sharon Klahre  
Syndax Pharmaceuticals, Inc.  
[sklahre@syndax.com](mailto:sklahre@syndax.com)  
Tel 781.684.9827

SNDX-G

 View original content: <https://www.prnewswire.com/news-releases/syndax-announces-participation-at-two-upcoming-investor-conferences-302051306.html>

SOURCE Syndax Pharmaceuticals, Inc.